NEFEGAN was the first ever treatment for IgAN fully approved by the US Food and Drug Administration Everest Medicines, a China-based biopharmaceutical company focused on the discovery, development, manufacturing and commercialisation of innovative medicines and vaccines, has announced that the Singapore Health Sciences Authority (HSA) has approved NEFEGAN for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease…
Singapore gives nod to China-based Everest Medicines’ drug for nephropathy treatment – BSA bureau
